根治性放疗联合水凝胶间隔物与前列腺切除术后放疗的直肠剂量比较
本研究比较了局限性前列腺癌根治性放疗(79.2 Gy)联合直肠周围水凝胶间隔物与前列腺切除术后放疗(70.2 Gy)的直肠剂量学差异。结果显示,水凝胶间隔物组直肠V65显著更低(中位数2.1% vs 10.7%,P < .001),且V60、V55、V50、V45也均显著更低(P < .005)。结论提示根治性放疗联合水凝胶间隔物的直肠剂量学更优,可能为前列腺癌初始治疗的共同决策提供参考。
要点
- 根治性放疗联合水凝胶间隔物组直肠V65中位数为2.1%,显著低于术后放疗组的10.7%。
- V60、V55、V50、V45在联合水凝胶间隔物组也均显著更低(P < .005)。
- 术后放疗 settings 下无法常规放置水凝胶间隔物,直肠剂量较高。
核心结论
- 根治性放疗(79.2 Gy)联合水凝胶间隔物的直肠剂量学优于术后放疗(70.2或66.6 Gy)。
研究设计与样本
- 回顾性研究,纳入2017至2018年接受常规分割放疗的前列腺癌患者51例,组1为根治性放疗联合水凝胶间隔物(79.2 Gy,16例),组2为术后放疗(70.2 Gy,35例),采用Mann-Whitney U检验比较直肠剂量学,Bonferroni校正阈值P < .005,线性回归分析预测因素。
主要发现
- 组1直肠V65中位数为2.1%(四分位距0.9%-3.1%),显著低于组2的10.7%(6.6%-14.5%)(P < .001)。
- 根治性放疗联合水凝胶间隔物与更低的V65独立相关(P < .001)。
- V60、V55、V50、V45在组1也均显著更低(P < .005)。
关键数值与推荐
- 组1处方剂量79.2 Gy,组2处方剂量70.2 Gy(结论提及66.6 Gy)。
- 直肠V65组1中位数2.1%(IQR 0.9%-3.1%),组2中位数10.7%(IQR 6.6%-14.5%),P < .001。
- V60、V55、V50、V45比较均P < .005。
临床怎么用
- 对于前列腺癌初始治疗决策,可参考本研究结果向患者说明根治性放疗联合水凝胶间隔物可能降低直肠高剂量照射体积。
- 尤其对于前列腺切除术后可能需要术后放疗的高危患者,共同决策时可考虑直肠剂量学差异。
局限性
- 回顾性研究,样本量较小(共51例),组间样本量不平衡(16例 vs 35例)。
- 术后放疗 settings 下无法常规放置水凝胶间隔物,组间比较存在固有差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Management options for localized prostate cancer include definitive radiation therapy (RT) or radical prostatectomy, with a subset of surgical patients requiring adjuvant or salvage RT after prostatectomy. The use of a peri-rectal hydrogel spacer in patients receiving definitive RT has been shown to reduce rectal doses and toxicity. However, in the postprostatectomy setting, a hydrogel spacer cannot be routinely placed. Therefore, we sought to compare rectal dosimetry between definitive RT with a hydrogel spacer versus postoperative RT. METHODS AND MATERIALS: We identified patients with prostate cancer who underwent conventionally fractionated RT. Rectal dosimetry was evaluated between 2 groups: definitive RT with a hydrogel spacer (79.2 Gy, group 1) and postoperative RT (70.2 Gy, group 2). Rectal dosimetry values were tabulated and compared using Mann-Whitney U test. We implemented a Bonferroni correction to account for multiple comparisons (threshold P < .005). Linear regression analysis evaluated predictors of candidate rectal dose-volume parameters. RESULTS: We identified 51 patients treated during years 2017 to 2018; 16 (31%) and 35 (69%) patients were included in groups 1 and 2, respectively. The rectal volume receiving ≥65 Gy (V65) was significantly lower in group 1 (median, 2.1%; interquartile range, 0.9%-3.1%) than in group 2 (10.7%, 6.6%-14.5%) (P < .001). Use of a hydrogel spacer in the definitive setting was independently associated with lower V65 (P < .001). Similar results were found for V60, V55, V50, and V45 (P < .005 for all). CONCLUSIONS: Rectal dosimetry is more favorable for definitive RT (79.2 Gy) with a hydrogel spacer compared with postoperative RT (70.2 or 66.6 Gy). This may inform shared decision-making regarding primary management of prostate cancer, especially among patients at high risk of needing postoperative RT after prostatectomy.
引用
- Yang DX, Verma V, An Y, et al. Radiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy. Adv Radiat Oncol. 2020. PMID: 33305083. doi:10.1016/j.adro.2020.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。